

D1 1. (Amended) A method for treating a T-cell mediated autoimmune disorder other than multiple sclerosis in a human subject comprising administering to the subject a therapeutically or prophylactically effective amount of [an antagonist of a receptor on a surface of a T-cell which mediates contact dependent helper effector functions] a gp39 (CD40-L) antagonist selected from the group consisting of an anti-gp39 antibody or fragment thereof that binds CD40-L, soluble CD40 and soluble CD40 fusion proteins.

Please cancel Claim 4 without prejudice.

D2 5. (Amended) The method of claim [4] 1, wherein the antagonist is an anti-gp39 antibody.

D3 9. (Amended) The method of claim 6, wherein the monoclonal antibody is a [chimeric] monoclonal antibody containing constant domains and variable regions derived from antibodies of different species.

IN THE ABSTRACT OF THE DISCLOSURE?

09/223,634

Kindly cancel the current Abstract and substitute the following new Abstract:

D4 Methods are described for treating and preventing T-cells mediated autoimmune diseases by the administration of gp39 (CD40 ligand) antagonists. Such diseases include by way of example, type 1 diabetes, oophoritis, and thyroiditis.